Antibodies against the human papillomavirus type 16 early proteins in human sera: Correlation of anti-e7 reactivity with cervical cancer

205Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.
Get full text

Abstract

By Western blot technique, 519 samples of human sera were tested for the presence of antibodies to the human papillomavirus (HPV) type 16 proteins E4 and E7 that had been expressed in Escherichia coli as fusion proteins. Sera were obtained from patients attending the University hospitals for reasons unrelated to HPV infections (controls), from patients with HPV-associated lesions, as well as from patients suffering from cervical cancer. Within the control population, 18.1% of them had antibodies that reacted with the E4 protein, and 3.9% of them had antibodies that reacted with the E7 protein. No sex-specific difference in the antibody prevalence was observed. The highest proportion of anti-E4 antibody-positive individuals (40.7%) was observed in the age group between 11 and 20 years. The frequency of anti-E4-positive sera was threefold higher in patients with HPV-associated genital lesions than that in age-matched controls. Antibodies against the HPV16 E7 protein were found 14 times more frequently in patients with cervical cancer, compared with age- and sex-matched controls (P

Cite

CITATION STYLE

APA

Jochmus-kudielka, I., Schneider, A., Braun, R., Kimmig, R., Koldovsky, U., Schneweis, K. E., … Gissmann, L. (1989). Antibodies against the human papillomavirus type 16 early proteins in human sera: Correlation of anti-e7 reactivity with cervical cancer. Journal of the National Cancer Institute, 81(22), 1698–1704. https://doi.org/10.1093/jnci/81.22.1698

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free